Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Capital Reinvestment Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Capital Reinvestment Ratio of 0.06x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥76.07 Million) in capital expenditures (CN¥4.69 Million). See Beijing Sun Novo Pharmaceutical Research (688621) net asset quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Sun Novo Pharmaceutical Research Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks Beijing Sun Novo Pharmaceutical Research Co Ltd's Capital Reinvestment Ratio across 8 annual periods. Check Beijing Sun Novo Pharmaceutical Research investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2024. For live market cap and broader valuation context, see market cap of Beijing Sun Novo Pharmaceutical Research.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.95x | CN¥32.02 Million | CN¥30.48 Million | ▲ +21.2% |
| 2023 | 0.79x | CN¥92.86 Million | CN¥72.96 Million | ▼ -21.4% |
| 2022 | 1.00x | CN¥103.96 Million | CN¥103.87 Million | ▲ +3.8% |
| 2021 | 0.96x | CN¥88.25 Million | CN¥84.96 Million | ▲ +124.3% |
| 2020 | 0.43x | CN¥62.99 Million | CN¥27.03 Million | ▼ -4.8% |
| 2019 | 0.45x | CN¥56.97 Million | CN¥25.67 Million | ▲ +21.1% |
| 2018 | 0.37x | CN¥44.11 Million | CN¥16.41 Million | ▼ -85.8% |
| 2017 | 2.62x | CN¥8.01 Million | CN¥20.96 Million | — |